Recent advances in the MM treatment landscape have identified B-cell maturation antigen (BCMA) as a tumor-associated antigen and, consequently, the target for multiple immunotherapies including chimeric antigen receptor T-cell (CAR-T) therapy, bispecific/trispecific antibodies (Bs/TsAbs) and antibody–drug conjugates (ADCs) [1]. The gene discussed is TNFRSF17; the disease is neoplasm.